Last edition
News about Global Pharma
Aurobindo's Lyfius Pharma Resumes Penicillin-G Production at Kakinada Plant
Lyfius Pharma, a wholly owned subsidiary of Aurobindo Pharma, has resumed Penicillin-G production after receiving the green light from the Andhra Pradesh Pollution Control Board (APPCB) to operate the Kakinada plant, which had been temporarily paused following a fire in April.
Global Pharma | 01/07/2025 | By Manvi | 1278
Fresenius Kabi Launches FDA Approved Denosumab Biosimilars in US
These denosumab biosimilars are approved by the FDA for all indications of the reference products, Prolia® (denosumab) and Xgeva® (denosumab), respectively.
Global Pharma | 01/07/2025 | By Manvi | 253
Torrent Pharma to Acquire Controlling Stake in JB Pharma from KKR in INR 25,689 Crore Deal
Torrent Pharmaceuticals has announced plans to acquire a controlling stake in JB Pharma from KKR in an INR 25,689 crore deal, paving the way for a merger that will significantly boost its Indian market position and global expansion strategy.
Global Pharma | 01/07/2025 | By Mrinmoy Dey | 409
Biocon Biologics Scales Up Insulin Access in Malaysia
Biocon Biologics has announced that its Malaysian subsidiary has crossed the milestone of supplying over 100 million recombinant human insulin cartridges to Malaysia’s Ministry of Health, reinforcing its commitment to affordable and accessible diabetes care.
Global Pharma | 30/06/2025 | By Mrinmoy Dey | 295
Cycle Pharmaceuticals' HARLIKU Gets FDA Approval
Cycle Pharmaceuticals announced that the FDA has approved HARLIKU (nitisinone) Tablets for the reduction of urine homogentisic acid (HGA) in adult patients with AKU.
Global Pharma | 30/06/2025 | By Manvi | 136
FDA Clears Archeus' IND for Prostate Cancer Therapy ART-101
Archeus Technologies announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ART-101, a novel receptor-based targeting small molecule that Archeus has developed for the imaging and treatment of prostate cancer.
Global Pharma | 30/06/2025 | By Manvi | 270
Alembic Pharmaceuticals has received final USFDA approval for its generic Doxorubicin Hydrochloride Liposome Injection, 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials, for the treatment of Ovarian Cancer, AIDS-Related Kaposi’s Sarcoma, and Multiple Myeloma.
Global Pharma | 30/06/2025 | By Manvi | 218
Ancora Heart Hits Enrollment Goal in CORCINCH-HF Trial for HFrEF Therapy
Ancora Heart, Inc. announced that it has reached the first enrollment milestone in the CORCINCH-HF pivotal trial evaluating the AccuCinch® Transcatheter Left Ventricular Restoration System in patients with heart failure with reduced ejection fraction (HFrEF).
Global Pharma | 27/06/2025 | By Manvi | 148
Stryker Receives US FDA 510(k) Clearance for Incompass Total Ankle System
Stryker announced it has received US Food and Drug Administration (FDA) 510(k) clearance for the Incompass® Total Ankle System, an implant intended for patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative arthritis.
Global Pharma | 27/06/2025 | By Manvi | 116
Avivomed Appoints Dan Brounstein as CEO and Board Member
Steve Brounstein has succeeded CEO Steve Masson, who retired from his role in May and will continue to work with the company in an advisory role.
Global Pharma | 27/06/2025 | By Abha | 348
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy